Synbiotic SE Logo

Synbiotic SE

A vertically integrated European group in the cannabis and industrial hemp markets.

SBX | F

Overview

Corporate Details

ISIN(s):
DE000A351MG9 (+6 more)
LEI:
48510041U2G1IWA3R418
Country:
Germany
Address:
Münsterstr. 336, 40470 Düsseldorf

Description

Synbiotic SE is a European corporate group focused on the medical cannabis and industrial hemp markets. The company operates a platform model, making strategic investments in ventures across these sectors to create synergies. Its business is vertically integrated, covering the entire value chain from cultivation, research, and development to the production, sales, and distribution of hemp- and cannabinoid-based products. The company's portfolio includes a wide range of high-quality hemp, CBD, and cannabis products, leveraging its expertise across the full supply chain from seed to shelf.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-17 17:16
SYNBIOTIC SE: DURCHFUHRUNG EINER KAPITALERHOHUNG BESCHLOSSEN
German 7.2 KB
2025-12-16 11:49
Strategic Investment: CANSOUL acquires stake in SYNBIOTIC
English 9.9 KB
2025-12-12 13:45
SYNBIOTIC SE: Bushdoctor GmbH beantragt Insolvenzverfahren
German 6.7 KB
2025-12-11 15:46
SYNBIOTIC SE: DURCHFUHRUNG EINER KAPITALERHOHUNG BESCHLOSSEN
German 7.1 KB
2025-11-18 10:41
SYNBIOTIC strengthens its presence at international events and monitors advance…
English 9.6 KB
2025-10-21 10:03
SYNBIOTIC welcomes Green Partys proposal for the Industrial Hemp Liberalization…
English 10.3 KB
2025-10-10 11:47
SYNBIOTIC SE: Anpassung der Umsatz- und Ergebnisprognose fur das Geschaftsjahr …
German 7.4 KB
2025-10-02 13:26
Positive Outlook: Cannabis Legalization Review and Trumps Endorsement Send Enco…
English 9.2 KB
2025-08-14 11:19
Across the pond: SYNBIOTIC attracts international investors with established in…
English 10.2 KB
2025-07-29 12:54
Revenue expected to triple by 2027: Focus on growth markets for medical cannabi…
English 10.9 KB
2025-06-11 11:48
Successful roadshow continues: SYNBIOTIC keeps expanding its presence in the ca…
English 9.3 KB
2025-04-23 09:24
SYNBIOTIC SE: HempConsult GmbH, Lending (free of charge) of 50,000 shares as p…
English 6.1 KB
2025-04-18 14:14
IRIS Capital invests in SYNBIOTIC's growth strategy
English 8.7 KB
2025-04-17 13:21
SYNBIOTIC SE: STRATEGISCHE PARTNERSCHAFT MIT IRIS CAPITAL INVESTMENT
German 6.8 KB
2025-04-01 15:13
SYNBIOTIC presents medical cannabis as a pastille for the German market for the…
English 8.7 KB

Automate Your Workflow. Get a real-time feed of all Synbiotic SE filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Synbiotic SE

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Synbiotic SE via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-11-13 Otto, Frank Supervisory board Other None 1,085,723.60 EUR
2023-11-28 Kruse, Daniel Other Buy None 19,794.19 EUR
2023-11-28 Kruse, Daniel Other Buy None 297.00 EUR
2023-10-23 Otto, Frank Supervisory board Other None 354,474.00 EUR

Peer Companies

Annexon, Inc. Logo
Clinical-stage biopharma developing complement medicines by inhibiting C1q.
United States of America
ANNX
ANTEROGEN CO., LTD. Logo
Develops and commercializes cell therapies and orphan drugs using adult stem cells.
South Korea
065660
Antibiotice S.A. Logo
Pharmaceutical firm manufacturing generic medicines, anti-infectives, and APIs.
Romania
ATB
Apellis Pharmaceuticals, Inc. Logo
Biopharmaceutical company developing therapies by targeting the complement cascade.
United States of America
APLS
Apimeds Pharmaceuticals US, Inc. Logo
Clinical-stage biopharma developing a bee venom drug and AI digital treasury solutions.
United States of America
APUS
Apogee Therapeutics, Inc. Logo
Clinical-stage biotech developing biologics for immunological and inflammatory diseases.
United States of America
APGE
Apollomics Inc. Logo
Clinical-stage biotech developing innovative oncology and combination therapies.
United States of America
APLM
Apontis Pharma AG Logo
Develops and markets fixed-dose combination drugs (Single Pills) for chronic diseases.
Germany
APPH
Applied Therapeutics, Inc. Logo
Clinical-stage biopharma developing novel drugs for rare metabolic and CNS diseases.
United States of America
APLT
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologics and biosimilar antibody-based therapeutics.
South Korea
003060

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.